Karyopharm to be delisted from Nasdaq following Chapter 11 filing

Karyopharm Therapeutics Inc. disclosed in an 8-K dated November 5, 2026 that it received a delisting notice from Nasdaq staff on November 4, 2026. The company and its subsidiary, KPT Texas LLC, had filed voluntary Chapter 11 bankruptcy petitions on November 2, 2026 in a Texas federal bankruptcy court.¹

Nasdaq staff determined that, as a result of the bankruptcy filing and under Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Karyopharm's securities will be delisted.¹ The staff cited several factors behind the determination, including the bankruptcy petitions and related public interest concerns, worries about the residual equity interest of existing shareholders, and doubts about the company's ability to keep meeting Nasdaq's listing requirements.¹ Although the notice said Karyopharm could appeal under Nasdaq's rules, the company stated it does not plan to do so.¹

The company's common stock will stop trading on Nasdaq when markets open on November 11, 2026, and Karyopharm will file a Form 25-NSE with the SEC to formally remove the shares from Nasdaq listing and registration.¹ Afterward, the stock is expected to move to over-the-counter trading on or after November 11, 2026, under the new ticker KPTIQ, replacing its former Nasdaq symbol KPTI.¹

The company warned shareholders about the risks of trading during this period. It said trading in its securities while the bankruptcy case is pending is highly speculative, with no guarantee that OTC trading will start or continue, and that prices may not reflect what shareholders ultimately recover in the case.¹ Under the reorganization plan filed with the bankruptcy court on November 2, 2026, Karyopharm said it expects existing equity securities to have no value and that holders will face a complete loss on their investment.¹